Search PubMed⌕ Search

Biomedical subjects

M Lechleitner

Publications and source records attributed to M Lechleitner.

64 records · Page 4Linked to original sources
PubMed1986

Macrophage infiltration in non-Hodgkin's lymphomas: a quantitative in situ study.

The frequency and distribution pattern of macrophages within 93 non-Hodgkin's lymphomas (NHL) were evaluated in situ by immunomorphometry using stereological methods. For the identification of macrophages (M phi), several antibodies (Mono 1, Mono 2, OKM 1) reactive with surface antigens on cells of the monocyte-macrophage series and cytochemical staining for acid phosphatase were applied. The average number of macrophages within lymph node tissue of NHL was 6,299 +/- 760 cells/microliter (similar to reactive lymphatic tissue: 6,559 +/- 1,027). The highest number of infiltrating macrophages was detected in immunoblastic NHL (17,306 +/- 2,773), differing significantly from other histological subtypes and reactive lymphatic tissue (p less than 0.005). The possible impact of tumor-infiltrating macrophages on lymphoma cell proliferation and differentiation is discussed.

Antibodies, Monoclonal↗
PubMed1986

The role of surgery in the combined management of small cell bronchial carcinoma.

Even after the introduction of modern chemotherapeutic regimens and radiotherapeutic approaches in the treatment of small cell bronchial carcinoma (SCLC), the results are still disillusioning. Long-term remissions are rare even in patients with limited disease. We review 66 patients with SCLC (limited disease) which we treated either by single therapies (chemotherapy, radiotherapy, surgery n = 16), or by different combinations of the possible therapeutic measures. Favorable results were achieved by a comprehensive treatment including operation, chemotherapy and prophylactic cranial and local irradiation: 11 of 15 patients survived 3 to 97 months after the onset of therapy, 4 of those more than 24 months. Based on our own experience and the results of other authors we feel that surgical resection should be again included as an essential part of treatment: tumor resection is the rational primary therapeutic approach for cases without lymph node metastases in the mediastinum and for tumors of uncertain histological type. If there is evidence of lymph node involvement in the mediastinum (N2), surgery should be performed after a remission has been successfully induced by chemotherapy (so-called adjuvant surgery).

Adult↗
PubMed1985

[Host reaction in non-Hodgkin's lymphomas: tumor infiltration with monocytes/macrophages].

The number and distribution of macrophages in deep frozen sections of various non-Hodgkin lymphomas (NHL) were evaluated in situ by immunomorphometry using stereological methods. The density of infiltration was correlated with clinical parameters. Several monoclonal antibodies reactive with antigens present on cells of the monocyte-macrophage series were tested in parallel. The density of macrophages within NHL of high malignancy with 11.3 X 10(3) +/- 1739 positive cells/microliter tumour tissue was higher than in those of low malignancy (4.7 X 10(3) +/- 628). The highest value of positive cells was found in immunoblastic lymphoma (17.3 X 10(3) +/- 2773), differing significantly from other histological subtypes of NHL and normal tissue (normal tissue: 6.5 X 10(3) +/- 1027, p less than 0.005). With regard to clinical parameters, localized NHL displayed lower infiltration numbers than generalized NHL. Possible mechanisms of influencing tumour growth are discussed in view of the large infiltration density of the monocyte macrophage series in NHL of unfavourable histology and advanced clinical stage.

Antibodies, Monoclonal↗
PubMed1985

Effect of human recombinant alpha-2- and gamma-interferon on the growth of human cell lines from solid tumors and hematologic malignancies.

We studied the growth effects of human recombinant interferon (IFN)-alpha-2 and -gamma on various human cell lines. Four cell lines from solid tumors (WiDr, CCL 185, BT 20, KB) and three cell lines from hematologic malignancies (U 937, U 266, MOLT 4) were chosen. The study was performed using two different assays: (1) a soft agar cloning assay, and (2) a monolayer and suspension culture. In the soft agar assay alpha-IFN inhibited colony growth of 6/6 lines tested (the line MOLT 4 could not be plated); in the monolayer assay it inhibited proliferation of 6/7 lines tested. Gamma-IFN showed inhibitory effects on 5/6 cell lines tested in the soft agar assay, but on one line (CCL 185) low concentrations of gamma-IFN led to a significant increase in the number of colonies. Using the monolayer assay, gamma-IFN showed inhibition of 6/7 lines tested, whereas a stimulation of growth could not be observed. With a combination of alpha- and gamma-IFN, synergistic effects were seen on a histiocytic cell line (U 937) in both assays and a marginal synergism on the T-cell line MOLT 4 in the monolayer assay.

Cell Division↗
PubMed1983

[Type, number and mode of distribution of cases of poisoning at the University Department of Internal Medicine, Innsbruck].

In the course of one year 357 patients were treated in our department for poisoning, nearly always with suicidal intent. Altogether 249 patients were admitted to the wards for 24 hours or longer, and 108 of these (44.6%) were taken into the intensive care unit. Apart from myocardial infarction (276 patients/year), poisoning is the most common reason for admission to the intensive care unit. The age distribution showed a maximum between 15 and 20 years. Only one case proved fatal, representing a mortality rate of 0.3%.

Adult↗
PubMed1983

[Recurrence in Hodgkin's disease: incidence, therapy and prognosis. (Experience with 134 patients)].

Of 157 patients with Hodgkin's disease treated between 1970 and 1981 an assessment of the clinical course was possible in 134 cases. Remissions were achieved in 120 patients (89%). 51 patients (43%) relapsed subsequently. The highest relapse rates were seen in advanced stages of the disease and in patients with unfavourable histological subgroups (mixed cellularity and lymphocyte depletion). Second remissions were achieved in 40 patients (78%), the remission being complete in 33 cases (65%). Patients who had received radiation therapy primarily, responded significantly better to secondary treatment than patients who had received chemotherapy initially. The predicted five-year survival rate is 70% for patients with complete remission after relapse and 34% for patients with partial remission. Though a relapse of Hodgkin's disease can frequently be treated with curative outcome, patients with certain high-risk factors (e.g. large mediastinal tumour, stage III2, lymphocyte depletion histology) need more intensive induction therapy.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1983

[Therapy of malignant lymphomas].

Prognostic factors in patients with Hodgkin's disease and the non-Hodgkin lymphomas are reviewed and discussed since they form the basis of the therapeutic approach to these conditions. Hodgkin's disease is treated according to stage, histology and other prognostic criteria and the appropriate management is presented in tabular form. In the non-Hodgkin lymphomas, prospective studies using the Kiel classification indicated that these lymphomas could be subdivided into types of low-, intermediate- and high-grade malignancy, each requiring different treatment modalities. An expectative approach is often, but not always, recommended in lymphomas of low malignancy. The natural history of lymphomas of high-grade malignancy is unfavourable and, usually, prolonged survival is observed only in those cases in which a complete remission is achieved. Our therapeutic approach to the various forms of these lymphomas is based on the stage of the disease and the respective schedules are summarized for lymphomas of low- and high-grade malignancy. Finally, the chances of cure in Hodgkin's disease and in the non-Hodgkin lymphomas are discussed and recent developments are mentioned.

Adolescent↗